NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









XellSmart

XellSmart

Private
SuzhouHealthcare & Life Scienceshttps://xellsmart.com

Last Round

Series C

Extension

Apr 2, 2026

Total Funding Raised

$185.64M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

XellSmart is a biotechnology company that develops clinical-grade, allogeneic, off-the-shelf, iPSC-derived cell therapies for central nervous system diseases such as Parkinson's and ALS.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine

Business Model

B2G

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

iPSC-derived cell therapyallogeneic cell therapyoff-the-shelf cell therapyinduced pluripotent stem cellsiPSCregenerative medicinestem cell therapyCNS disease treatmentneurodegenerative diseaseParkinson's disease treatmentspinal cord injury treatmentneural progenitor cellsclinical-stage biotechGMP manufacturingINDOrphan Drug Designation

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

XellSmart Comparables

Compare XellSmart with similar companies based on industry and business-model similarity.

XellSmart comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Shanghai UniXell Biotechnology
87%
Kenai Therapeutics
85%
Nuwacell Biotechnologies Co., Ltd.
82%

XellSmart Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series C ExtensionApr 2, 2026
Series BJan 14, 2026
Series A ExtensionApr 1, 2023
Series A ExtensionNov 8, 2022
Series AJan 9, 2022
Pre Seed
Sep 8, 2021

XellSmart Investors

Notable investors and investment history

XellSmart investors
InvestorRounds
Huatai Zijin Investment Co., Ltd.Series A Extension
FigSeries A Extension
Junshan InvestmentSeries A Extension
Oriza HoldingsSeries A Extension
Tianjin TEDA Science and Technology Investment Co., Ltd.Pre Seed, Angel
YuanBio Venture CapitalPre Seed
Next CapitalSeries A Extension, Pre Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 21, 2026

    Monthly visitors increased 63% MoM.

  • Apr 2, 2026

    $69.1M round led by China Reform Fund.

XellSmart Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

XellSmart Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about XellSmart's valuation, stock price, and market status.

Firmographic Details

HeadquartersSuzhou
Employee Range3
Year Founded2021
Last FundingApr 2, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.